121 related articles for article (PubMed ID: 37080351)
1. Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma.
Zhou X; Li Y; Yang C; Chen D; Wang T; Liu T; Yan W; Su Z; Peng B; Ren X
Life Sci; 2023 Aug; 327():121698. PubMed ID: 37080351
[TBL] [Abstract][Full Text] [Related]
2. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
5. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
Acharya B; Chaijaroenkul W; Na-Bangchang K
J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
[TBL] [Abstract][Full Text] [Related]
6. Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma.
Liu T; Zhu G; Yan W; Lv Y; Wang X; Jin G; Cui M; Lin Z; Ren X
J Pharmacol Exp Ther; 2020 May; 373(2):279-289. PubMed ID: 32102917
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway.
Ma J; Feng J; Zhou X
Exp Mol Pathol; 2020 Aug; 115():104466. PubMed ID: 32446859
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
11. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
12. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
13. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
[TBL] [Abstract][Full Text] [Related]
14. Up-regulated LINC00261 predicts a poor prognosis and promotes a metastasis by EMT process in cholangiocarcinoma.
Gao J; Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Cui Y; Zhong X
Pathol Res Pract; 2020 Jan; 216(1):152733. PubMed ID: 31812439
[TBL] [Abstract][Full Text] [Related]
15. β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation.
Acharya B; Chajaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2573-2581. PubMed ID: 36037109
[TBL] [Abstract][Full Text] [Related]
16. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.
Clapéron A; Mergey M; Nguyen Ho-Bouldoires TH; Vignjevic D; Wendum D; Chrétien Y; Merabtene F; Frazao A; Paradis V; Housset C; Guedj N; Fouassier L
J Hepatol; 2014 Aug; 61(2):325-32. PubMed ID: 24704591
[TBL] [Abstract][Full Text] [Related]
17. Expression of endoplasmic reticulum oxidoreductase 1-α in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells.
Yan W; Wang X; Liu T; Chen L; Han L; Xu J; Jin G; Harada K; Lin Z; Ren X
Cancer Manag Res; 2019; 11():6727-6739. PubMed ID: 31410063
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
[TBL] [Abstract][Full Text] [Related]
19. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
[TBL] [Abstract][Full Text] [Related]
20. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
